Exclusive Summary

• - Broad demand: addresses large T2D, heart failure, and CKD populations with multi-specialty use cases.
• - Timing tailwind: key IPs roll off in many countries between 2025–2029; emerging markets already expanded, enabling staged TT/distribution by country.
• - Proven value: listed on WHO EML and strongly recommended by ADA/ESC/KDIGO, with clear cardio-renal benefits.
• - Strong cost edge: 80–95% discount vs originator; LMIC monthly therapy can reach roughly US$3–10, supporting tenders and reimbursement.
• - Differentiation levers: first-to-file/first-to-launch in constrained markets, FDCs and full label coverage, and superior compliance/registration to build barriers.